[go: up one dir, main page]

PL3286311T3 - Sposób leczenia nowotworów złośliwych - Google Patents

Sposób leczenia nowotworów złośliwych

Info

Publication number
PL3286311T3
PL3286311T3 PL16769720T PL16769720T PL3286311T3 PL 3286311 T3 PL3286311 T3 PL 3286311T3 PL 16769720 T PL16769720 T PL 16769720T PL 16769720 T PL16769720 T PL 16769720T PL 3286311 T3 PL3286311 T3 PL 3286311T3
Authority
PL
Poland
Prior art keywords
malignancies
treatment
Prior art date
Application number
PL16769720T
Other languages
English (en)
Inventor
Robert H. Pierce
Adil Daud
Original Assignee
Oncosec Medical Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Incorporated filed Critical Oncosec Medical Incorporated
Publication of PL3286311T3 publication Critical patent/PL3286311T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36002Cancer treatment, e.g. tumour
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
PL16769720T 2015-03-26 2016-03-24 Sposób leczenia nowotworów złośliwych PL3286311T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562138793P 2015-03-26 2015-03-26
US201662309131P 2016-03-16 2016-03-16
PCT/US2016/024079 WO2016154473A1 (en) 2015-03-26 2016-03-24 Method for the treatment of malignancies
EP16769720.0A EP3286311B1 (en) 2015-03-26 2016-03-24 Method for the treatment of malignancies

Publications (1)

Publication Number Publication Date
PL3286311T3 true PL3286311T3 (pl) 2021-09-13

Family

ID=56978697

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16769720T PL3286311T3 (pl) 2015-03-26 2016-03-24 Sposób leczenia nowotworów złośliwych

Country Status (8)

Country Link
US (2) US10426847B2 (pl)
EP (2) EP3286311B1 (pl)
JP (2) JP6879996B2 (pl)
CA (1) CA2981049A1 (pl)
DK (1) DK3286311T3 (pl)
ES (1) ES2873093T3 (pl)
PL (1) PL3286311T3 (pl)
WO (1) WO2016154473A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390311B (es) 2013-12-05 2025-03-20 Rfemb Holdings Llc Presentacion de antigeno de cancer mejorado a celulas que presentan por la descomposicion electrica de membrana por radiofrecuencia (rf-rmb) como un mecanismo adyuvante para la inmunoterapia.
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
PL3286311T3 (pl) 2015-03-26 2021-09-13 Oncosec Medical Incorporated Sposób leczenia nowotworów złośliwych
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
TW202428236A (zh) * 2016-01-15 2024-07-16 美商Rfemb控股有限公司 癌症之免疫治療
EP4209190A1 (en) 2016-06-27 2023-07-12 Galvanize Therapeutics, Inc. System comprising a generator and a catheter with an electrode for treating a lung passageway
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
WO2018057943A1 (en) * 2016-09-23 2018-03-29 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP2021508533A (ja) 2017-12-26 2021-03-11 ギャラリー,インコーポレイテッド 様々な用途のためのエネルギー送達の最適化
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
WO2019136305A1 (en) * 2018-01-04 2019-07-11 Neumedicines Inc. Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー,リミテッド Pd-1に対する単一ドメイン抗体及びその変異体
WO2020247598A1 (en) * 2019-06-05 2020-12-10 Emory University Photolysis to unlock caged protein therapeutics
JP7586890B2 (ja) 2019-07-16 2024-11-19 ガルヴァナイズ セラピューティクス,インコーポレイテッド パルス電界による生殖器の治療
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
JP2022549138A (ja) 2019-09-18 2022-11-24 インターガラクティック セラピューティクス インコーポレイテッド 合成dnaベクターおよびその使用法
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
KR102490645B1 (ko) * 2020-07-16 2023-01-25 고려대학교 산학협력단 흡수에너지 기반 전기장 암치료 계획 시스템 및 방법
US20240299540A1 (en) * 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501445A (ja) 1999-06-08 2003-01-14 ユーエイビー リサーチ ファンデーション 外来遺伝子を発現するヘルペス単純ウイルスおよびそれによる癌の治療方法
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8802643B1 (en) * 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
EA200501937A1 (ru) * 2003-05-30 2006-08-25 Университет Южной Флориды Способ лечения злокачественных опухолей
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
CA3101783C (en) * 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US8994173B2 (en) * 2013-06-26 2015-03-31 International Business Machines Corporation Solder bump connection and method of making
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
PL3286311T3 (pl) 2015-03-26 2021-09-13 Oncosec Medical Incorporated Sposób leczenia nowotworów złośliwych
WO2017106795A1 (en) 2015-12-18 2017-06-22 Oncosec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
WO2018057943A1 (en) 2016-09-23 2018-03-29 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy

Also Published As

Publication number Publication date
EP3286311B1 (en) 2021-05-05
DK3286311T3 (da) 2021-05-17
JP2018509477A (ja) 2018-04-05
JP6879996B2 (ja) 2021-06-02
CA2981049A1 (en) 2016-09-29
WO2016154473A1 (en) 2016-09-29
US20200000938A1 (en) 2020-01-02
EP3286311A1 (en) 2018-02-28
US11564999B2 (en) 2023-01-31
HK1251614A1 (en) 2019-02-01
JP2021119181A (ja) 2021-08-12
ES2873093T3 (es) 2021-11-03
WO2016154473A8 (en) 2017-04-20
US10426847B2 (en) 2019-10-01
EP3881860A1 (en) 2021-09-22
EP3286311A4 (en) 2018-11-21
US20180318393A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
PL3286311T3 (pl) Sposób leczenia nowotworów złośliwych
IL259783A (en) Methods of treatment of malignant diseases
IL279627A (en) A method for treating depression
ZA201802420B (en) Combination therapy for treating malignancies
ZA201803166B (en) Combination therapy for treating malignancies
EP3242947A4 (en) Method for the treatment of malignancies
SG11201607130RA (en) Combination method for treatment of cancer
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL259996A (en) Combinations for cancer treatment
IL258684A (en) Combined treatment for malignancy
ZA201802088B (en) Combination therapy for treating malignancies
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
GB201410116D0 (en) Method of treatment
IL253028B (en) treatment method
GB201602802D0 (en) Method of treatment
SG11201706885RA (en) Novel treatment method
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
GB201512139D0 (en) Methods of treatment
HK1262105A1 (en) Methods of treatment of malignancies
GB201511017D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment